Please type a plus sign (+) inside this box -



Approved for use through 10/31/2002. OMB 0651-0031 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Subs	titute for form 1449A	/PTO		Complete if Known			
				Application Number	10/049,868		
IN	FORMATIC	ONDISC	LOSURE	Filing Date	February 11, 2002		
ST	TATEMENT	BY APF	PLICANT	First Named Inventor	Hans Deckmyn and Nancy Cauwenberghs		
-		•		Group Art Unit			
	(use as many s	sheets as nec	essary)	Examiner Name			
Shee	t 1	of	2	Attorney Docket Number	522-1778		

	U.S. PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	U.S. Paten Number	Kind Code ²	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		5,336,667		Kirby	08-09-1994				
		5,486,361		Gralnick	01-23-1996				
					<u> </u>				
	•		·						
		-							
		•							
									

	FOREIGN PATENT DOCUMENTS										
Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant				
		Office ³	Number ⁴	Kind Code ⁶ (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁶			
			WO-00/26667-A1		Miller	05-11-2000					
						ļ					
						1:		╂			
			<u> </u>								
							-	+			
	·					 		1			
		 									


Examiner	Date
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETEDFORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	te for form 1449B	/PTO		Complete if Known			
			01.001100	Application Number	10/049,868		
INF	JRWAII	ONDIS	CLOSURE	Filing Date	February 11, 2002		
STA	TEMEN.	TRY A	PPLICANT	First Named Inventor	Hans Deckmyn and Nancy Cauwenberghs		
				Group Art Unit			
	(use as mai	ny sheets as	necessary)	Examiner Name			
Sheet	2	of	2	Attorney Docket Number	522-1778		

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	itoni (book, nigaazino, louina), bonai, by nibosiun, balaiou, clo.), uale, balacca, volumbensale illinibensal.						
		Reverter, "Inhibition of Platelet - mediated, Tissue Factor induced", J. Clin. Invest, vol a8, no. 3, 8/96,pp 863-874						
		Pareti, "Interaction of porcine von Willebrand factor with the platelet", British J. of Haematology, vol 82, 1992, pp 81 - 86						
	:	Becker, "Effects of an Antiplatlet Glycoprotein Ib Antibody on", Blood, vol 74, no.2, 8/1/89, pp 690-694						
		Ward, "Epitope and functional characterization of the CD42", Platlet antigens, pp 1336-1337						
		Cowenberghs, "Antithrombotic Effect of Platelet Glycoprotein Ib- Blocking", Arteriosclerosis, Thrombosis abd Vascular Biology,"						
		Coller, "A Murine Monoclonal Antibody that Completely Blocks", J. Clin. Invest. vol 72, 7/83, pp 325-338						
<u> </u>		Shetler, "Antithrombotic Assessment of the Effects of Combination", 1996, American Heart Association, pp 1719 - 1725						
		Simoons, "Randomized Trial of a GPIIb/IIIa Platelet Receptor", Circulation, vol 89, no2, 2/94, pp 596 - 603						
		Schultz, "Use of C7E3 Fab in Conjunction With Primary Coronary", Catherization and Coardiovascular Diagnosis, vol 39, 1996, pp 143 - 148	-					
		Lincoff, "Platelet Glycoprotein IIb/IIIa Receptor Blocade And", New England J. of Med., vol 336, no 24, 6/12/97, pp 1689-1697						
		Gold, "PharmacodynamicStudy of F (ab)2 Fragments of", J. Clin. Invest., vol 86, 8/90, pp 651 - 659						

Name and Address of the Owner, where the Owner, which is the Owner, which is the Owner, where the Owner, which is the Owner,			
Examiner		Date	
Signature		Considered	

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.